The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
NEW YORK, NY / ACCESSWIRE / July 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible viola...
NEW YORK, NY / ACCESSWIRE / July 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible viola...
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ...
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible viola...
LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ...
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible viola...
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible viola...
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX). Such investors are advised ...
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible viola...